In Australia, the incidence of oesophageal cancer (also known as oesophageal adenocarcinoma (OAC) or cancer of the gullet) has been increasing. Surgery is the only curative treatment. Surgery to remove the cancer usually requires removal of most of the oesophagus and some of the stomach. Unfortunately, the cancer returns in most cases after surgery. Chemotherapy, with or without radiotherapy, before surgery has been shown to improve outcomes after surgery.

Trial Summary:

The DOCTOR study aims to compare the effectiveness of pre-operative treatment with cisplatin, 5 fluorouracil and docetaxel, with or without radiotherapy, in treating people who have shown a poor early response to standard chemotherapy for adenocarcinoma of the oesophagus and/or gastroesophageal junction.

Supported By:

NHMRC

Eligibility:

Patients with with resectable adenocarcinoma of the oesophagus or oesophagogastric junction

Registration ID:

ACTRN12609000665235

Participation:

Australia

Australian Lead Group:

AGITG

Status:

In follow-up

Activation Date:

1/03/2010

Chairs:

Andrew Barbour (Australia)

Contact:

doctor.study@sydney.edu.au